MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

GLP-1 receptor dual agonist

  • Home
  • GLP-1 receptor dual agonist
Mazdutide: A Novel Dual Agonist Demonstrates Significant Weight Loss in Adults with Obesity or Overweight
Posted inDiabetes & Endocrinology news

Mazdutide: A Novel Dual Agonist Demonstrates Significant Weight Loss in Adults with Obesity or Overweight

Posted by MedXY By MedXY 08/22/2026
Mazdutide, a once-weekly glucagon and GLP-1 receptor dual agonist, delivers clinically meaningful weight reduction in adults with obesity or overweight, with higher doses yielding superior outcomes and manageable safety profiles.
Read More
  • Navigating Surgical Decisions in Patients with Dementia: Clinician Challenges and Insights
  • Beyond Survival: Longitudinal Health-related Quality of Life After Hepatectomy for High-risk Colorectal Liver Metastases
  • Beyond Stenosis: How Carotid Plaque Calcification Patterns on CTA Predict Stroke Risk
  • Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data
  • Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top